Brokerages Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Target Price at $19.88

Jasper Therapeutics, Inc. (NASDAQ:JSPR) has received an average rating of “Moderate Buy” from the twelve ratings firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating and seven have issued a buy rating on the company. The average 12 month target price among analysts that have covered the stock in the last year is $19.8750.

A number of analysts have recently issued reports on JSPR shares. Rodman & Renshaw started coverage on shares of Jasper Therapeutics in a report on Tuesday, January 13th. They set a “buy” rating and a $17.00 price target for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Jasper Therapeutics in a research note on Thursday, January 22nd.

Institutional Trading of Jasper Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of JSPR. Bank of Montreal Can boosted its stake in Jasper Therapeutics by 120.4% during the second quarter. Bank of Montreal Can now owns 158,133 shares of the company’s stock worth $878,000 after buying an additional 86,393 shares during the period. Simplify Asset Management Inc. acquired a new position in shares of Jasper Therapeutics in the 3rd quarter worth approximately $1,450,000. Marex Group plc acquired a new position in shares of Jasper Therapeutics in the 2nd quarter worth approximately $74,000. Kingdon Capital Management L.L.C. boosted its position in shares of Jasper Therapeutics by 93.5% during the 3rd quarter. Kingdon Capital Management L.L.C. now owns 1,324,845 shares of the company’s stock worth $3,153,000 after purchasing an additional 640,138 shares during the period. Finally, Two Sigma Investments LP acquired a new stake in Jasper Therapeutics in the 3rd quarter valued at approximately $96,000. 79.85% of the stock is currently owned by hedge funds and other institutional investors.

Jasper Therapeutics Stock Up 0.7%

NASDAQ JSPR opened at $1.36 on Thursday. The business’s fifty day simple moving average is $1.66 and its 200-day simple moving average is $2.16. The firm has a market cap of $38.05 million, a PE ratio of -0.23 and a beta of 3.08. Jasper Therapeutics has a 52 week low of $1.26 and a 52 week high of $7.19.

Jasper Therapeutics (NASDAQ:JSPR) last released its quarterly earnings data on Monday, November 10th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.01) by ($0.12). Research analysts expect that Jasper Therapeutics will post -4.47 EPS for the current year.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.